Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZNCF AstraZeneca	$134.75 -1.8%	$144.01	$120.64 ▼ $175.00	N/A	N/A	2,122 shs	1,084 shs
CMOPF Cosmo Pharmaceuticals	C$55.00	C$65.85	C$55.00 ▼ C$95.00	N/A	N/A	350 shs	N/A
CSPCY CSPC Pharmaceutical Group	C$3.13 -0.8%	C$2.57	C$2.15 ▼ C$3.82	N/A	N/A	30,277 shs	516 shs
JCRRF JCR Pharmaceuticals	$4.57	$4.57	$4.30 ▼ $4.70	N/A	N/A	200 shs	N/A

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZNCF AstraZeneca	0.00%	-3.61%	-3.82%	-2.32%	-0.44%
CMOPF Cosmo Pharmaceuticals	0.00%	0.00%	-12.41%	-23.61%	-27.63%
CSPCY CSPC Pharmaceutical Group	0.00%	+11.79%	+26.21%	+42.92%	+1.62%
JCRRF JCR Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-12.45%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AZNCF AstraZeneca	0.3651 of 5 stars	0.0	2.0	1.7	0.0	1.2	0.8	0.0
CMOPF Cosmo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CSPCY CSPC Pharmaceutical Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
JCRRF JCR Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZNCF AstraZeneca	N/A	N/A	N/A
CMOPF Cosmo Pharmaceuticals	N/A	N/A	N/A
CSPCY CSPC Pharmaceutical Group	N/A	N/A	N/A
JCRRF JCR Pharmaceuticals	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZNCF AstraZeneca	N/A	N/A	N/A	N/A	N/A	N/A
CMOPF Cosmo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
CSPCY CSPC Pharmaceutical Group	N/A	N/A	N/A	N/A	N/A	N/A
JCRRF JCR Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZNCF AstraZeneca	N/A	$0.82	165.13	∞	N/A	N/A	N/A	N/A	4/29/2025 (Estimated)
CMOPF Cosmo Pharmaceuticals	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CSPCY CSPC Pharmaceutical Group	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
JCRRF JCR Pharmaceuticals	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	5/13/2025 (Estimated)

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZNCF AstraZeneca	$2.80	2.08%	N/A	343.14%	N/A
CMOPF Cosmo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CSPCY CSPC Pharmaceutical Group	N/A	N/A	N/A	N/A	N/A
JCRRF JCR Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest JCRRF, AZNCF, CMOPF, and CSPCY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/6/2025	AZNCF AstraZeneca		$2.10		2/19/2025	2/21/2025	3/24/2025

(Data available from 1/1/2013 forward)

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZNCF AstraZeneca	40.87%
CMOPF Cosmo Pharmaceuticals	N/A
CSPCY CSPC Pharmaceutical Group	N/A
JCRRF JCR Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
AZNCF AstraZeneca	N/A
CMOPF Cosmo Pharmaceuticals	N/A
CSPCY CSPC Pharmaceutical Group	N/A
JCRRF JCR Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZNCF AstraZeneca	83,500	N/A	N/A	Not Optionable
CMOPF Cosmo Pharmaceuticals	319	N/A	N/A	Not Optionable
CSPCY CSPC Pharmaceutical Group	23,500	N/A	N/A	Not Optionable
JCRRF JCR Pharmaceuticals	934	N/A	N/A	Not Optionable

JCRRF, AZNCF, CMOPF, and CSPCY Headlines

Recent News About These Companies

JCR Pharmaceuticals Nominates New Audit & Supervisory Board Members

April 25 at 3:36 AM | tipranks.com

JCR Pharmaceuticals Begins Construction of New Drug Product Plant

February 25, 2025 | tipranks.com

JCR Pharmaceuticals' Research Presentations at WORLDSymposiumâ„¢ 2025 Showcase Research from Its Investigational Treatments for Lysosomal Storage Disorders

February 5, 2025 | businesswire.com

JCR Pharmaceuticals Showcases Promising Data at WORLDSymposium™ 2025

February 5, 2025 | tipranks.com

Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain

February 3, 2025 | biospace.com

JCR Pharmaceuticals Co., Ltd. (4552) Gets a Hold from Jefferies

January 29, 2025 | markets.businessinsider.com

JCR Pharmaceuticals to Present at the 21st Annual WORLDSymposium™ 2025

January 28, 2025 | finance.yahoo.com

JCR Pharmaceuticals to Showcase Innovative Therapies at WORLDSymposium 2025

January 28, 2025 | tipranks.com

JCR Pharmaceuticals, Modalis Therapeutics Ink Research Deal to Develop CNS Gene Therapy

January 6, 2025 | precisionmedicineonline.com

JCR Pharmaceuticals and Modalis Therapeutics Advance Gene Therapy Collaboration

January 5, 2025 | tipranks.com

JCR Pharmaceuticals and Modalis Advance Joint Gene Therapy Research

January 5, 2025 | tipranks.com

JCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy

January 5, 2025 | businesswire.com

JCR Pharmaceuticals Gains Orphan Drug Status in Japan

December 25, 2024 | tipranks.com

JCR Pharmaceuticals doses first patient in paediatric growth hormone trial

December 23, 2024 | msn.com

JCR Pharmaceuticals Initiates Phase III Clinical Trial of JR-142 in Japan, a Long-Acting Growth Hormone Therapy

December 20, 2024 | businesswire.com

JCR Pharmaceuticals Launches Key JR-142 Clinical Trial

December 19, 2024 | tipranks.com

MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Announce Initiation of First Dosing in Phase I/II Clinical Trial of JR-446 for Mucopolysaccharidosis Type IIIB in Japan

December 5, 2024 | businesswire.com

JCR Pharmaceuticals Initiates Clinical Trial for MPS IIIB

December 3, 2024 | tipranks.com

JCR Pharmaceuticals Faces Financial Decline Amid Strategic Changes

November 18, 2024 | tipranks.com

JCR Pharmaceuticals Completes Share Buyback for Strategic Growth

November 1, 2024 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JCRRF, AZNCF, CMOPF, and CSPCY Company Descriptions

AstraZeneca OTCMKTS:AZNCF

$134.75 -2.49 (-1.81%)

As of 04/25/2025 12:29 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Cosmo Pharmaceuticals OTC:CMOPF

C$55.00 0.00 (0.00%)

As of 04/25/2025

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers' diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy. It is also in the development of Breezula (clascoterone), a novel androgen receptor inhibitor that targets androgen receptors in the scalp, currently expecting phase III trials; Rifamycin SV MMX IBS-D, a formulation to treat colonic infections and irritable bowel syndrome with diarrhoea, currently completed phase II proof of concept clinical trials; CB-03-10 (cortexolone 17 -valerate-21-propionate), an oral androgen receptor antagonist for treatment solid tumors, currently under phase I studies; and CB-01-33 (colesevelam) for the treatment of bile acid diarrhea, currently under preclinical studies. The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, Parmascience Inc., RedHill Biopharma Ltd., Dr. Falk Pharma, Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

CSPC Pharmaceutical Group OTCMKTS:CSPCY

C$3.13 -0.03 (-0.79%)

As of 04/25/2025 12:08 PM Eastern

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, North America, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company has a strategic partnership with Pfizer Inc. to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.

JCR Pharmaceuticals OTCMKTS:JCRRF

$4.57 0.00 (0.00%)

As of 04/25/2025

JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices and laboratory instruments; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies; and a. joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time